AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02205814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Single intra-articular injection of placebo
Study NCT03766308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Highland Barley Diet
Description: Highland Barley Diet
Study NCT03766308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ADA diet
Description: ADA diet
Study NCT04069091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'Enjoy your Bump' (iloodottaa.fi) online self-help intervention
Description: The intervention employs elements of cognitive behavioral therapy: empathic, clear and sensitive communication with women and their families, problem self-formulation of solutions to problems, behavioral activation, identification and changing negative automated negative thoughts, addressing low confidence, and promoting problem- solving and relapse prevention.~The Enjoy your Bump intervention has been adapted to the Finnish culture and healthcare setting (ilodottaa.fi).
Study NCT04084301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High CPB flow
Description: Target CPB flow 2.9 L/min/m2 throughout the CPB period
Study NCT00642460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg (patients>=30kg) or 12mg/kg (patients \<30kg) iv every 2 weeks. In Part III, administration frequency may be reduced to every 3 and every 4 weeks, respectively, according to an optional alternative dosing schedule.
Study NCT00642460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv every 2 weeks for 12 weeks
Study NCT00642460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Description: as prescribed
Study NCT00642460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Description: as prescribed
Study NCT00642460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: as prescribed
Study NCT00642460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: as prescribed
Study NCT00642460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: orally, as prescribed
Study NCT00642460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corticosteroids
Description: orally, as prescribed
Study NCT02518958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Study NCT02518958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02633254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance guided High Intensity Focused Ultrasound
Description: Targeted vessel ablation of type 3 uterine fibroids with magnetic resonance guided high intensity focused ultrasound
Study NCT02124018 — intervention group
Intervention type: PROCEDURE
Intervention: Programmed ventricular stimulation
Description: Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation
Study NCT02124018 — intervention group
Intervention type: DEVICE
Intervention: ICD implantation
Description: ICD implantation in patients with induced VT in programmed ventricular stimulation
Study NCT03878030 — intervention group
Intervention type: DRUG
Intervention: nusinersen
Description: Subjects will receive nusinersen and be observed with motor assessments for 24 months
Study NCT02183337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Study NCT02183337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356
Study NCT02183337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 + Pioglitazone
Study NCT02183337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356 + Pioglitazone
Study NCT02183337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Study NCT02183337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Study NCT02507180 — intervention group
Intervention type: OTHER
Intervention: LEFt clinical decision rule
Description: The LEFt rule~Predictor Points Left leg symptoms +1 Extremity swelling (≥ 2 cm difference in calf circumference +1 First trimester symptom onset +1~Clinical probability Unlikely: 0 or 1 point Likely: > 1 point
Study NCT01165788 — intervention group
Intervention type: PROCEDURE
Intervention: Semi structured personal interview
Description: A trained research assistant will conduct in-person, in-depth semi-structured interviews at a location of the participants choosing. Participants will be asked to discuss their experiences with cancer, focusing especially on how their cancer affected their (1) work/education (2) relationships with their family (spouse, children, parents, siblings and other relatives) (3) their other social relationships
Study NCT02027818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Observation of the correlation between fluorescence and margins of the tumour after IV injection of ICG
Study NCT00993512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphinex (TPCS2a)
Description: intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
Study NCT00993512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
Study NCT00993512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Illumination with CeramOptec laser
Description: intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
Study NCT00835640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg tablets
Description: 1 x 180 mg
Study NCT00835640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALLEGRA® 180 mg tablets
Description: 1 x 180 mg
Study NCT03465462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: group/arm C (control group)
Description: Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
Study NCT03465462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: group/arm D (diet group)
Description: Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
Study NCT03465462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: group/arm S (supplementation group)
Description: Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
Study NCT02638389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: evaluate the efficacy and safety of sirolimus in these patients
Study NCT02495246 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd3-EBO-Z
Study NCT02495246 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad26.ZEBOV
Study NCT00420615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone and Omeprazole
Study NCT00420615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone + Midalzolam
Study NCT03401567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Elbow bending exercises with blood flow restriction will be performed to the exercise group during 6 weeks for 3 times a week. The first set of exercises will be 30 repetitions then 3 sets of 15 repetitions. Totally 75 repetitions will be performed. 30 seconds rest interval between sets will be given.
Study NCT03409211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PEVCO
Description: All subjects will receive PEVCO for 6 more weeks.
Study NCT03409211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement Capsules without Coconut Oil
Description: All subjects will receive placebo (PBO) for 3 weeks
Study NCT02321189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LONGEVINEX
Description: let everyone of the participants oral 1 capsule containing 100 mg LONGEVINEX
Study NCT02321189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: let everyone of the participants oral 1 capsule containing 100 mg placebo
Study NCT03262025 — intervention group
Intervention type: PROCEDURE
Intervention: Operated
Description: Patients were either managed conservatively or underwent emergency laparotomy
Study NCT03172806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: To compare the ability of the clinical scores, all patients included in this study underwent a polysomnography.
Study NCT03394599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraTrainer + Motiview
Description: TheraTrainer will be used in conjunction with Motiview.
Study NCT03394599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TheraTrainer Only
Description: TheraTrainer will be used.
Study NCT00931723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine fumarate XR
Description: Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
Study NCT00931723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Quetiapine fumarate XR
Description: Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
Study NCT00931723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
Study NCT00931723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral treatment twice daily.
Study NCT02629848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motesanib
Description: Motesanib (AMG 706) 5 x 25 mg tablets
Study NCT02629848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Motesanib placebo-matching tablets
Study NCT02629848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV
Study NCT02629848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel IV
Study NCT02629848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV
Study NCT02629848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV
Study NCT03937648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COL-144 50mg
Description: COL-144 50mg
Study NCT03937648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COL-144 100mg
Description: COL-144 100mg
Study NCT03937648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COL-144 200mg
Description: COL-144 200mg
Study NCT03937648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COL-144 400mg
Description: COL-144 400mg
Study NCT03937648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01774253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Study NCT03381365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CuraSeal Percutaneous Intraluminal Closure System
Study NCT01402076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 20mg daily dosing, Days 4-20
Study NCT01402076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: 4mg, single dose, Days 3 and 20
Study NCT01402076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 10mg, single dose, Days 1 and 18
Study NCT03352557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: Administered as specified in treatment arm.
Study NCT03352557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in treatment arm.
Study NCT00907803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-246 400 mg
Description: Capsules, 400 mg daily for 14 days
Study NCT00907803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-246 600 mg
Description: Capsules, 600 mg daily for 14 days
Study NCT00907803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, once daily for 14 days
Study NCT01212497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation coaching
Description: Participants interact with virtual coach to obtain instruction in mindfulness meditation and coaching support.
Study NCT03730831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: 8-20 sessions: 1 lifeline session, 6-17 sessions narrative exposure, 1-2 sessions of future-oriented counselling~-> Intervention is a part of the second work program. First work program focueses on cross-sectional data and includes a systematic record of psychopathology in participants with schizophrenia sepctrum disorder.
Study NCT01430923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: refrigeration free latanoprost
Description: latanoprost Eye drops 0.005% once daily, 3 months
Study NCT01430923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost eye drops
Description: latanoprost eye drops 0.005% w/v, once daily, 3 months
Study NCT02281474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Study NCT01598337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Patients continue their maintenance dose not inturrupted by surgery , 81 mg daily
Study NCT01598337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirofiban
Description: Tirofiban infusion as specified by investigators to start after hemostasis been established
Study NCT01598337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: Tirofiban infusion as specified by investigators to start after hemostasis been established
Study NCT01598337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75 mg orally started 6-8hours before surgery
Study NCT01598337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 75 mg orally started 6-8hours before surgery
Study NCT04423796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted early mobilization
Description: The early mobilization is done by robotic assistance devices.
Study NCT04423796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early mobilization
Description: Early mobilization by health care professionals without robotic assistance.
Study NCT01894217 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic testing and reporting for SLCO1B1*5 allele
Description: Blood test for SLCO1B1\*5 allele; reporting of test results to provider and participant
Study NCT03510052 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet Modification Pilot Program (DPM)
Description: Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit.
Study NCT01291472 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketorolac Tromethamine
Description: After dilution (solution for injection, 10 mg/1ml) in 50-100 ml bag of normal saline drug will be administered by iv bolus, through a peripherally inserted venous catheter, 30 mg, 3 times in one day. The intended duration of administration is 5-10 minutes.
Study NCT02349516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squalamine Lactate Ophthalmic Solution 0.2%
Description: Squalamine Lactate Ophthalmic Solution 0.2% eye drop to be administered to study eye either BID or QID for 52 weeks
Study NCT02349516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Squalamine Lactate Ophthalmic Solution 0.2%
Description: Squalamine Lactate Ophthalmic Solution 0.2% eye drop to be administered to study eye either BID or QID for 52 weeks
Study NCT00845520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens implantation +1.00 D postop target
Description: Lens implantation +1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
Study NCT00845520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens implantation -1.00 D postop target
Description: Lens implantation -1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
Study NCT00845520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens implantation 0.00 D postop target
Description: Lens implantation 0.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
Study NCT02871661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Volunteers will take 25 milligrams of this medication every day from their enrollment until completing eight weeks long.
Study NCT02871661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotherapy
Description: Volunteers will be taught to contract their pelvic floor muscles right before stretching it, following a home protocol, every day for eight weeks long.
Study NCT02871661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IC (Quark)
Description: Volunteers will visit physical therapy clinic once a week to receive twenty minutes of electrical stimulation with Interferential Current (Duapex 961 of Quark Medical manufacturer) in their perineal area, for eight weeks long.
Study NCT01072838 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: APBI (Dose Escalation)
Description: Accelerated, hypofractionated partial breast radiotherapy.~3 dose schemes followed for 6 months each.
Study NCT01072838 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Contura MLB Breast Brachytherapy Catheter
Study NCT01180231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxonidine (Physiotens)
Description: Subjects will be asked to take moxonidine, dosage to be determined prior to commencement by a medical doctor for 6 months duration.
Study NCT01180231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Subjects will be asked to follow dietary plans designed by a qualified nutritionist for 6 months.
Study NCT03064594 — intervention group
Intervention type: PROCEDURE
Intervention: Cornual pregnancy
Description: we will get the information of operative time, blood loss and postoperative pregnancy and delivery rate.
Study NCT04617574 — intervention group
Intervention type: DEVICE
Intervention: AEON Endostapler
Description: Surgery with AEON Endostapler
Study NCT04617574 — intervention group
Intervention type: DEVICE
Intervention: Endo GIA Reloads with Tri-Staple Technology
Description: Surgery with Endo GIA Reloads with Tri-Staple Technology
Study NCT01876966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: 200 mg ETR b.i.d. from Day 1 to Day 21 with a single 200 mg dose of ETR in the morning on Day 22
Study NCT01876966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir
Description: DRV/rtv 600/100 mg b.i.d. from Day 1 to Day 21 with a single dose of DRV/rtv in the morning on Day 22
Study NCT01876966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether/lumefantrine
Description: 3 days of treatment with artemether/lumefantrine 80/480 mg (6 doses of 4 tablets \[20/120 mg\] at 0, 8, 24, 36, 48, and 60 hours)
Study NCT02509858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thyroxine
Description: treatment with 50μg of thyroxine once daily for two months.
Study NCT02509858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: treatment with 50μg of placebo, once daily, for two months.
Study NCT02509858 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)
Study NCT02509858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)
Study NCT03004625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daclatasvir
Description: to evaluate the treatment efficacy and safety of the drug in HCV patients
Study NCT03004625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asunaprevir
Description: to evaluate the treatment efficacy and safety of the drug in HCV patients
Study NCT03004625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: to evaluate the treatment efficacy and safety of the drug in HCV patients